Navigation Links
Resverlogix Appoints A. Brad Cann as Chief Financial Officer
Date:10/13/2009

TSX Exchange Symbol: RVX

CALGARY, Oct. 13 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that Mr. A. Brad Cann, CA will be joining the firm on October 26, 2009 as its Chief Financial Officer. Mr. Cann will be responsible for leading the Company's financial reporting and compliance, accounting, treasury, internal audit and legal. In addition he will share responsibilities for investing, financial and partnering transactions. Resverlogix is a biotechnology company focused on delivering novel therapeutics for diseases with significant unmet medical needs. The Company is developing an oral small molecule therapeutic to treat atherosclerosis and cardiovascular disease.

"We are very pleased to add Brad to our team of professionals. He has a number of areas of expertise that will round out the collective expertise within Resverlogix including developing strategic initiatives, securing financings for publicly traded companies and he is a Chartered Business Valuator. Brad succeeds Mr. Kelly McNeill who was Resverlogix's previous CFO and he will be nominated as a corporate director at the upcoming October 15th, 2009 Annual General Meeting," said Donald J. McCaffrey, President and CEO of Resverlogix.

Previous to joining Resverlogix Mr. Cann worked for Royal Host Real Estate Investment Trust where he held a number of positions including most recently Executive Vice President and Chief Financial Officer. Prior to joining Royal Host, Brad worked as a financial and business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company. Previously, Brad held various positions with a chartered accounting firm. Brad holds a Bachelor of Commerce Degree from the University of Saskatchewan and he is a Chartered Accountant and a Chartered Business Valuator.

About Resverlogix Corp.


'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
2. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
3. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
4. Resverlogix Provides Quarterly Update
5. Resverlogix Board of Directors Update
6. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
7. Resverlogix Announces Closing of Debt Redemption
8. Resverlogix Eliminates Sixty Percent of Remaining Debt
9. Resverlogix Issues a Management Statement
10. Resverlogix Board of Directors Update
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available ... NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for extreme ... are able to enter fat cells, inhibiting the formation of new fat. Upon ...
(Date:7/28/2015)... A n ew UK company ... commercialising innovative medicines to transform patient quality of life and ... team; blue chip investor ... Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that it ... blue chip institutional investors and simultaneously acquired a portfolio of ...
(Date:7/28/2015)... July 28, 2015 Seahorse Bioscience, the ... is the provider of XF Technology which is ... research areas. As the links between mitochondrial function ... metabolism is escalating rapidly.   Recently, ... Nature Publishing Group (NPG) featuring XF Technology, including ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... Inc. (NYSE: BMR ) today announced it will ... after the market closes on Wednesday, November 3, 2010. ... Kent Griffin, President, and Greg N. Lubushkin, Chief Financial Officer, ... Time on Thursday, November 4, 2010 to discuss the company,s ...
... announced a partnership to advance the use of biofuels by ... effort involves entrepreneurs John Fox ,92 and Wayne Arden, who ... achieve multiple benefits, including reducing risks to American troops and ... With energy demands growing at home bases along with ...
... Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com ) announced ... to the Company and a member of the Company,s ... of the reverse stock split proposal being considered at ... "Having been intimately involved in the drug development world ...
Cached Biology Technology:BioMed Realty Trust to Report 2010 Third Quarter Results 2Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 2Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 3Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 4Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 2Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 3Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 4
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... HOUSTON (Aug. 20, 2008) The genetic code of a ... of genes function in humans and other species. A study ... the genetic code of Trichoplax , a simple saltwater creature ... common household aquarium. "We,re trying to identify, in the ...
... biodegradable polymers called polyketals and their derivatives may improve ... acute liver failure and inflammatory bowel disease by delivering ... locations in the body. "The polyketal microparticles we ... inside the body to the diseased area as quickly ...
... Researchers here have found a way to convert ethanol ... new catalyst makes hydrogen from ethanol with 90 percent ... Umit Ozkan, professor of chemical and biomolecular engineering ... is much less expensive than others being developed around ...
Cached Biology News:Genome of saltwater creature could aid understanding of gene grouping 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 3A better way to make hydrogen from biofuels 2A better way to make hydrogen from biofuels 3
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
... Kit, Protein, 1. Based on the ... the kit gives essentially colorless backgrounds ... Kit, Protein provides convenient, reproducible and ... gels in less than two hours.The ...
Biology Products: